Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas

V. Lorusso, A. Paradiso, M. Guida, F. Berardi, M. De Lena

Research output: Contribution to journalArticlepeer-review


Twenty-two patients affected by relapsed or refractory non-Hodgkin's lymphoma (NHL) were treated with a combination of ifosfamide (IFO) at the dose of 1.2 g/m2 intravenous (i.v.) (1 h infusion) for 5 consecutive days with mesna as uroprotector plus mitoxantrone (NOV) at the dose of 12 mg/m2 i.v. on day 1; both drugs were recycled every 3-4 weeks. Of 21 evaluable patients, overall response observed as 57% (38% complete response and 19% partial response with a median duration of response of 7 months (5-23+). Dose-limiting toxicity was represented by leukopenia (grade III-IV in 43% of cases); severe thrombocytopenia was observed less frequently (grade III-IV in 19% of cases). This hematologic toxicity prevented administration of therapy every 3 weeks as initially planned. However, the complete hematological recovery, usually observed at the fourth week, permitted therapy administration to all patients without dose reduction. Low-grade lymphomas responded to treatment as well as intermediate or high grade lymphomas. Moreover, patients treated with third- or fourth-line chemotherapy also responded. However, response was observed in 11/13 (85%) relapsed patients as compared to 2/8 (25%) refractory cases. The combination of IFO plus NOV is active in heavily pretreated patients with NHL. Nevertheless, the study of a larger number of patients is necessary to better define the exact role of this combination as ''salvage'' therapy for NHL.

Original languageEnglish
Pages (from-to)492-495
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number6
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas'. Together they form a unique fingerprint.

Cite this